Abstract:1 Tramadol is a centrally acting analgesic with low opioid receptor affinity and, therefore, presumably additional mechanisms of analgesic action. Tramadol and its main metabolite O‐desmethyltramadol were tested on rat central noradrenergic neurones of the nucleus locus coeruleus (LC), which are involved in the modulation of nociceptive afferent stimuli. 2 In pontine slices of the rat brain the spontaneous discharge of action potentials of LC cells was recorded extracellularly. (−)‐Tramadol (0.1–100μm), (+)‐tramadol (0.1–100 μm), (−)‐O‐desmethyltramadol (0.1–100 μm) and (+)‐O‐desmetnyltramadol (0.01–1 μm) inhibited the firing rate in a concentration‐dependent manner. (+)‐O‐desmetnyltramadol had the highest potency, while all other agonists were active at a similar range of concentrations. 3 (−)‐Tramadol (10, 100 μm) was less inhibitory in brain slices of rats pretreated with reserpine (5 mg kg−1, 5 h before decapitation) than in controls. 4 The effect of (−)‐tramadol (10 μm) was abolished in the presence of the α2‐adrenoceptor antagonist, rauwolscine (1 μm), whilst that of (+)‐O‐desmetnyltramadol (0.3 μm) virtually disappeared in the presence of the opioid antagonist, naloxone (0.1 μm). (+)‐Tramadol (30 μm) and (−)‐O‐desmethyltramadol (10 μm) became inactive only in the combined presence of naloxone (0.1 μm) and rauwolscine (1 μm). 5 In another series of experiments, the membrane potential of LC neurones was determined with intracellular microelectrodes. (−)‐Tramadol (100 μm) inhibited the spontaneous firing and hyperpolarized the cells; this effect was abolished by rauwolscine (1 μm). (+)‐O‐desmethyltramadol (10 μm) had a similar but somewhat larger effect on the membrane potential than (−)‐tramadol. The (+)‐O‐desmethyltramadol‐ (10 μm) induced hyperpolarization was abolished by naloxone (0.1 μm). 6 The hyperpolarizing effect of noradrenaline (30 μm) was potentiated in the presence of (−)‐tramadol (100 μm), but not in the presence of (+)‐O‐desmethyltramadol (10 μm). There was no potentiation of the noradrenaline (30 μm) effect, when the cells were hyperpolarized by current injection to an extent similar to that produced by (−)‐tramadol (100 μm). 7 Both noradrenaline (100 μm) and (−)‐tramadol (100 μm) decreased the input resistance. 8 The results confirm that the analgesic action of tramadol involves both opioid and non‐opioid components. It appears that (−)‐tramadol inhibits the uptake of noradrenaline and via a subsequent increase in the concentration of endogenous noradrenaline indirectly stimulates α2‐adrenoceptors. (+)‐O‐desmethyltramadol seems to stimulate directly opioid μ‐receptors. The effects of (+)‐tramadol and (−)‐O‐desmetnyltramadol consist of combined μ‐opioid and α2‐adrenergic components.

Metformin Promotes AMP-activated Protein Kinase-independent Suppression of ΔNp63α Protein Expression and Inhibits Cancer Cell Viability

Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition

Metformin Attenuates Hepatoma Cell Proliferation by Decreasing Glycolytic Flux Through the HIF-1α/PFKFB3/PFK1 Pathway.

Potential Effect of EGCG on the Anti-Tumor Efficacy of Metformin in Melanoma Cells

Comparison of Three Commercially Available Peptide-Based Immunoglobulin G (IgG) and IgA Assays to Microimmunofluorescence Assay for Detection of Chlamydia trachomatis Antibodies

Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis

Effects of the central analgesic tramadol and its main metabolite, O‐desmethyltramadol, on rat locus coeruleus neurones

High-dose metformin induces a low-glucose dependent genotoxic stress

Metformin triggers the intrinsic apoptotic response in human AGS gastric adenocarcinoma cells by activating AMPK and suppressing mTOR/AKT signaling

Abstract 6636: Metformin suppresses tumor immune evasion through downregulation of PD-L1 expression in cancer cells and PD-1 expression in NK cells and T cells

Antidiabetic drug metformin suppresses tumorigenesis through inhibition of mevalonate pathway enzyme HMGCS1

Proteomic Analysis Reveals That Metformin Suppresses PSMD2, STIP1, and CAP1 for Preventing Gastric Cancer AGS Cell Proliferation and Migration

High Glucose Represses the Anti-Proliferative and Pro-Apoptotic Effect of Metformin in Triple Negative Breast Cancer Cells

Metformin and Cancer Glucose Metabolism: At the Bench or at the Bedside?

Metformin exerts anti-tumor effects via Sonic hedgehog signaling pathway by targeting AMPK in HepG2 cells.

Metformin Displays Anti-Myeloma Activity and Synergistic Effect with Dexamethasone in in Vitro and in Vivo Xenograft Models.

Cell adhesion: Promoting partnerships

Metformin-treated cancer cells modulate macrophage polarization through AMPK-NF-κB signaling

Molecular Mechanisms of Metformin for Diabetes and Cancer Treatment

Metformin Synergistically Suppress Tumor Growth with Doxorubicin and Reverse Drug Resistance by Inhibiting the Expression and Function of P-glycoprotein in MCF7/ADR Cells and Xenograft Models

Metformin suppresses CRC growth by inducing apoptosis via ADORA1.